drugset / Trial / NCT02339129

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

NCT02339129

Phase 2 Completed 72 enrolled Strategic Science & Technologies, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2, prospective, randomized, dual-center, double-blind, placebo-controlled, parallel-group study designed to determine the dosing interval, efficacy and safety of SST-0225 (5.4 grams, applied up to 6 times in 24 hours, over a 48-hour dosing period) for the treatment of pain associated with DOMS.

Timeline

Start
2014-11
Primary completion
2015-02
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule 400 mg Topical

Indications

No indication recorded.